Overview

Treatment of Diabetes After Gastric Bypass With Sitagliptin

Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether Januvia (sitagliptin phosphate 100mg) is safe and effective for the treatment of Type 2 Diabetes in patients who have had Gastric Bypass.
Phase:
N/A
Details
Lead Sponsor:
Blandine Laferrere
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Sitagliptin Phosphate